Journal of Shanghai Jiao Tong University (Medical Science) >

2025 , Vol. 45 >Issue 1: 122 - 128

DOI: https://doi.org/10.3969/j.issn.1674-8115.2025.01.015

Case report

A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma

  • DU Fang ,
  • ZHOU Lingyun ,
  • CHEN Jiao ,
  • LIU Danbo ,
  • XIANG Hongxian ,
  • CHEN Haifei
Expand
  • Department of Hematology, Luohu People's Hospital, Guangdong Province, Shenzhen 518005, China
CHEN Haifei, E-mail: Chhf1224@163.com.

Received date: 2024-05-15

  Accepted date: 2024-09-27

  Online published: 2025-01-28

Fold

Abstract

Multiple myeloma (MM) remains an incurable disease, with most patients experiencing multiple relapses before ultimately progressing to refractory stage. Extramedullary infiltration is a common manifestation of relapse. However, distinguishing synchronous multifocal extramedullary infiltration from secondary malignancies poses significant diagnostic challenges. This study presents a case of relapsed refractory MM with multifocal extramedullary infiltration, diagnosed as coexistence of multiple myeloma extramedullary infiltration and pulmonary adenocarcinoma through multidisciplinary team (MDT) collaboration. Such coexistence is exceedingly rare in clinical practice and introduces substantial complexity in diagnosis and treatment planning. Through a comprehensive case report and literature review, this paper explores the diagnostic and therapeutic approaches to managing multifocal extramedullary infiltration coexisting with secondary malignancies in MM, highlighting the pivotal role of MDT in achieving precise diagnosis and optimizing patient outcomes.

Key words： relapsed and refractory multiple myeloma; extramedullary infiltration; pulmonary adenocarcinoma; synchronous coexistence; diagnosis and treatment

Cite this article

DU Fang , ZHOU Lingyun , CHEN Jiao , LIU Danbo , XIANG Hongxian , CHEN Haifei . A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(1) : 122 -128 . DOI: 10.3969/j.issn.1674-8115.2025.01.015

References

1 中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订) [J]. 中华内科杂志, 2022, 61(5): 480-487.
  Chinese Hematology Association, Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision) [J]. Chinese Journal of Internal Medicine, 2022,61(5): 480-487.
2 CASTANEDA O, BAZ R. Multiple myeloma genomics: a concise review[J]. Acta Med Acad, 2019, 48(1): 57-67.
3 MOREAU P, GARFALL A L, VAN DE DONK N W C J, et al. Teclistamab in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2022, 387(6): 495-505.
4 MOREAU P, KUMAR S K, SAN MIGUEL J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group[J]. Lancet Oncol, 2021, 22(3): e105-e118.
5 USMANI S Z, QUACH H, MATEOS M V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(1): 65-76.
6 de WEERS M, TAI Y T, van der VEER M S, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J]. J Immunol, 2011, 186(3): 1840-1848.
7 AGARWAL R, GUPTA R, BHASKAR A, et al. Synchronous presentation of multiple myeloma and lung cancer[J]. J Clin Oncol, 2008, 26(35): 5814-5816.
8 KAISER M F, CROFT J, SHAH P, et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment[J]. Br J Haematol, 2020, 189(1): e1-e3.
9 WANG Z, DENG H, ZHANG L, et al. Daratumumab for refractory IgD multiple myeloma with lung cancer and persistent thrombocytopenia: a case report [J]. Clin Lab, 2021, 67(11):2589.
10 DONG H H, LI J, KANG L, et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: a case report and review of the literature[J]. Oncol Lett, 2022, 23(6): 195.
11 ZUO W, ZHU X, YANG J, et al. Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: a case report[J]. Medicine (Baltimore), 2017, 96(1): e5787.
12 LIN J, ZHU H, LU X, et al. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses[J]. Intern Med, 2010, 49(21): 2341-2346.
13 GIBSON S J, COOPER J D, PHAM K, et al. Prognostic impact of second primary malignancies in multiple myeloma: an ASCO CancerLinQ discovery analysis of the modern era[J]. Am J Hematol, 2023, 98(11): E325-E327.
14 KLEBER M, IHORST G, TERHORST M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score[J]. Blood Cancer J, 2011, 1(9): e35.
15 ENGELHARDT M, IHORST G, LANDGREN O, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years[J]. Haematologica, 2015, 100(10): 1340-1349.
16 MACLACHLAN K, DIAMOND B, MAURA F, et al. Second malignancies in multiple myeloma; emerging patterns and future directions[J]. Best Pract Res Clin Haematol, 2020, 33(1): 101144.
17 JONES J R, CAIRNS D A, GREGORY W M, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial[J]. Blood Cancer J, 2016, 6(12): e506.
18 ORMEROD A, FAUSEL C A, ABONOUR R, et al. Observations of second primary malignancy in patients with multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(2): 113-117.
19 SCHRANK Z, CHHABRA G, LIN L, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance[J]. Cancers (Basel), 2018, 10(7): E224.
20 EGUREN-SANTAMARIA I, SANMAMED M F, GOLDBERG S B, et al. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice[J]. Clin Cancer Res, 2020, 26(16): 4186-4197.
21 PALUMBO A, AVET-LOISEAU H, OLIVA S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group[J]. J Clin Oncol, 2015, 33(26): 2863-2869.
Options
Outlines

/

〈 〉